
Punongbayan & Araullo20th Floor, Tower 1
The Enterprise Center
6766 Ayala Avenue
1200 Makati City
Philippines

T +63 2 8988 2288

Report of Independent Certified Public Accountants to Accompany Income Tax Return

The Board of Directors**Sun Pharma Philippines, Inc.*****[A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.]***

17F Unit 3 Milestone @ Fifth Avenue

5th Avenue Bonifacio Global City, Fort Bonifacio

1634 Taguig City NCR, Fourth District Philippines

We have audited the financial statements of Sun Pharma Philippines, Inc. (the Company) for the year ended March 31, 2026, on which we have rendered the attached report dated May 18, 2026.

In compliance with Revenue Regulations V-20, we are stating that no partner of our Firm is related by consanguinity or affinity to the president, manager or principal stockholder of the Company.

PUNONGBAYAN & ARAULLO

By: Arman B. Neptuno
Partner

CPA Reg. No. 0148776

TIN 428-244-641

PTR No. 10770768, January 6, 2026, Makati City

SEC Group A Accreditation

Partner - No. 148776-SEC (until financial period 2029)

Firm - No. 0002 (until financial period 2030)

BIR AN 08-002551-048-2023 (until November 14, 2026)

BOA/PRC Cert. of Reg. No. 0002/P-020 (until August 12, 2027)

May 18, 2026

Report of Independent Auditors

The Board of Directors

Sun Pharma Philippines, Inc.

[A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.]

17F Unit 3 Milestone @ Fifth Avenue

5th Avenue Bonifacio Global City, Fort Bonifacio

1634 Taguig City NCR, Fourth District Philippines

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Sun Pharma Philippines, Inc. (the Company), which comprise the statements of financial position as at March 31, 2026 and 2025, and the statements of comprehensive income, statements of changes in capital deficiency and statements of cash flows for the years then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2026 and 2025, and its financial performance and its cash flows for the years then ended in accordance with Philippine Financial Reporting Standards (PFRS Accounting Standards).

Basis for Opinion

We conducted our audits in accordance with Philippine Standards on Auditing (PSA). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics for Professional Accountants in the Philippines (Code of Ethics) together with the ethical requirements that are relevant to our audits of the financial statements in the Philippines, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 to the financial statements, which indicates that the Company has substantial capital deficiency of P275.6 million and P335.3 million as at March 31, 2026 and 2025, respectively. This condition indicates the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern entity. In response to this matter, the Company's management launched its Primary Care division in the fourth quarter of FY2026 and added new molecules to its Oncology portfolio. Moreover, the Company is exploring opportunities to further expand its product portfolio with new molecules. The Company's management also continues to strengthen the strategy to expand its sales and continuously generate profit by continuous intensive marketing of its products. Management is confident that the Company will be able to recover from losses in the next succeeding years. In 2026 and 2025, the Company generated operating income amounting to P119.3 million and P35.1 million, respectively. The Company's ultimate parent company has also committed to provide the Company with financial assistance to maintain it as going concern and enable it to meet its liabilities as and when they fall due until the next reporting period. Accordingly, the accompanying Company's financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and the settlement of liabilities in the normal course of business. In connection with our audit, we have performed audit procedures to evaluate management's assumptions as to the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with PFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

Our audits were conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplementary information for the year ended March 31, 2026 required by the Bureau of Internal Revenue as disclosed in Note 23 to the financial statements is presented for purposes of additional analysis and is not a required part of the basic financial statements prepared in accordance with PFRS Accounting Standards. Such supplementary information is the responsibility of management. The supplementary information has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

PUNONGBAYAN & ARAULLO

By: Arman B. Neptuno
Partner

CPA Reg. No. 0148776
TIN 428-244-641
PTR No. 10770768, January 6, 2026, Makati City
SEC Group A Accreditation
Partner - No. 148776-SEC (until financial period 2029)
Firm - No. 0002 (until financial period 2030)
BIR AN 08-002551-048-2023 (until November 14, 2026)
BOA/PRC Cert. of Reg. No. 0002/P-020 (until August 12, 2027)

May 18, 2026

SUN PHARMA PHILIPPINES, INC.
[A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.]
STATEMENTS OF FINANCIAL POSITION
MARCH 31, 2026 AND 2025
(Amounts in Philippine Pesos)

	<u>Notes</u>	<u>2026</u>	<u>2025</u>
<u>ASSETS</u>			
CURRENT ASSETS			
Cash	4	P 138,670,574	P 150,812,105
Trade and other receivables - net	5	373,542,154	261,525,170
Inventories - net	6	208,604,022	148,822,344
Other current assets	7	<u>33,542,601</u>	<u>32,157,891</u>
Total Current Assets		<u>754,359,351</u>	<u>593,317,510</u>
NON-CURRENT ASSETS			
Property and equipment - net	8	53,454,095	50,496,559
Right-of-use assets - net	9	43,767,862	23,488,822
Deferred tax asset	15	38,354,011	-
Other non-current assets - net	7	<u>7,628,985</u>	<u>2,907,149</u>
Total Non-current Assets		<u>143,204,953</u>	<u>76,892,530</u>
TOTAL ASSETS		<u>P 897,564,304</u>	<u>P 670,210,040</u>
<u>LIABILITIES AND CAPITAL DEFICIENCY</u>			
CURRENT LIABILITIES			
Trade and other payables	10	P 747,206,998	P 650,603,600
Advances from parent company	16	341,490,675	322,717,687
Lease liabilities	9	16,565,280	7,762,844
Income tax payable		<u>28,563,606</u>	<u>744,787</u>
Total Current Liabilities		<u>1,133,826,559</u>	<u>981,828,918</u>
NON-CURRENT LIABILITIES			
Retirement benefit obligation	14	9,102,254	5,979,988
Lease liabilities	9	<u>30,203,728</u>	<u>17,691,096</u>
Total Non-current Liabilities		<u>39,305,982</u>	<u>23,671,084</u>
Total Liabilities		<u>1,173,132,541</u>	<u>1,005,500,002</u>
CAPITAL DEFICIENCY			
Capital stock	17	8,653,400	8,653,400
Revaluation reserve	14	(417,626)	21,713
Deficit		<u>(283,804,011)</u>	<u>(343,965,075)</u>
Capital Deficiency		<u>(275,568,237)</u>	<u>(335,289,962)</u>
TOTAL LIABILITIES AND CAPITAL DEFICIENCY		<u>P 897,564,304</u>	<u>P 670,210,040</u>

See Notes to Financial Statements.

SUN PHARMA PHILIPPINES, INC.
[A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.]
STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED MARCH 31, 2026 AND 2025
(Amounts in Philippine Pesos)

	Notes	<u>2026</u>	<u>2025</u>
REVENUES - Net	11	P 834,142,791	P 652,633,822
COST OF GOODS SOLD	12	<u>277,226,055</u>	<u>243,149,454</u>
GROSS PROFIT		556,916,736	409,484,368
SELLING AND ADMINISTRATIVE EXPENSES	12	<u>437,576,092</u>	<u>374,356,276</u>
OPERATING PROFIT		119,340,644	35,128,092
OTHER CHARGES - Net	13	(<u>63,362,516</u>)	(<u>21,580,082</u>)
PROFIT BEFORE TAX		55,978,128	13,548,010
TAX EXPENSE (INCOME)	15	(<u>4,182,936</u>)	<u>9,207,505</u>
NET PROFIT		60,161,064	4,340,505
OTHER COMPREHENSIVE INCOME (LOSS)	14	(<u>439,339</u>)	<u>287,945</u>
TOTAL COMPREHENSIVE INCOME		<u>P 59,721,725</u>	<u>P 4,628,450</u>

See Notes to Financial Statements.

SUN PHARMA PHILIPPINES, INC.
[A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.]
STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
FOR THE YEARS ENDED MARCH 31, 2026 AND 2025
(Amounts in Philippine Pesos)

	Capital Stock (see Note 17)	Revaluation Reserve (see Note 14)	Deficit	Total
Balance at April 1, 2025	P 8,653,400	P 21,713	(P 343,965,075)	(P 335,289,962)
Total comprehensive income (loss)	<u>-</u>	<u>(439,339)</u>	<u>60,161,064</u>	<u>59,721,725</u>
 Balance at March 31, 2026	 <u>P 8,653,400</u>	 <u>(P 417,626)</u>	 <u>(P 283,804,011)</u>	 <u>(P 275,568,237)</u>
 Balance at April 1, 2024	 P 8,653,400	 (P 266,232)	 (P 348,305,580)	 (P 339,918,412)
Total comprehensive income	<u>-</u>	<u>287,945</u>	<u>4,340,505</u>	<u>4,628,450</u>
 Balance at March 31, 2025	 <u>P 8,653,400</u>	 <u>P 21,713</u>	 <u>(P 343,965,075)</u>	 <u>(P 335,289,962)</u>

See Notes to Financial Statements.

SUN PHARMA PHILIPPINES, INC.
[A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.]
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED MARCH 31, 2026 AND 2025
(Amounts in Philippine Pesos)

	<u>Notes</u>	<u>2026</u>	<u>2025</u>
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		P 55,978,128	P 13,548,010
Adjustments for:			
Net unrealized loss on foreign exchange transactions	13	59,437,425	10,472,204
Depreciation and amortization	8, 9	26,082,768	22,945,501
Impairment loss on trade and other receivables	5	14,597,011	3,055,205
Loss on inventory obsolescence - net	6	14,199,291	12,366,863
Gain on disposals of assets	8	(408,837)	(982,515)
Interest expense on lease liabilities	9	214,263	282,437
Interest income	4, 5	(73,290)	(77,940)
Operating income before working capital changes		170,026,759	61,609,765
Increase in trade and other receivables		(126,613,996)	(36,058,167)
Increase in inventories		(73,980,969)	(36,775,166)
Increase in other current assets		(1,384,710)	(7,365,868)
Increase in other non-current assets		(4,721,836)	(93,601)
Increase in trade and other payables		55,938,961	121,682,497
Increase in retirement benefit obligation		2,536,481	1,552,182
Cash generated from operations		21,800,690	104,551,642
Interest received		73,290	77,940
Cash paid for taxes		(6,205,810)	(8,462,718)
Net Cash From Operating Activities		<u>15,668,170</u>	<u>96,166,864</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisitions of property and equipment	8	(20,241,432)	(18,193,365)
Proceeds from sale of property and equipment	8	408,837	982,515
Net Cash Used in Investing Activities		(19,832,595)	(17,210,850)
CASH FLOWS FROM FINANCING ACTIVITY			
Payment of lease liabilities	9	(7,977,106)	(7,911,180)
NET INCREASE (DECREASE) IN CASH		(12,141,531)	71,044,834
CASH AT BEGINNING OF YEAR	4	<u>150,812,105</u>	<u>79,767,271</u>
CASH AT END OF YEAR	4	<u>P 138,670,574</u>	<u>P 150,812,105</u>

Supplemental Information on Non-cash Investing and Financing Activities —

The Company recognized additional right-of-use assets amounting to P29.1 million in 2026. Lease liabilities also increased by the same amount (see Note 9). There was no similar transaction in 2025.

See Notes to Financial Statements.

SUN PHARMA PHILIPPINES, INC.
(A Wholly Owned Subsidiary of Sun Pharma (Netherlands) B.V.)
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2026 and 2025
(Amounts in Philippine Pesos)

1. GENERAL INFORMATION

1.1 Corporate Information

Sun Pharma Philippines, Inc. (the Company) was incorporated and registered with the Philippine Securities and Exchange Commission (SEC) on December 8, 2011 primarily to engage in the business of marketing and distribution on wholesale of pharmaceutical, cosmetics and chemical products.

The Company is a wholly owned subsidiary Sun Pharma (Netherlands) B.V. (Parent company), a private limited liability company under Dutch law incorporated in Netherlands, is engaged to trade including import, export, purchase and sale in pharmaceutical and related products mainly manufactured by Sun Pharmaceutical Industries Limited – India (the ultimate parent company) and supply to the overseas related parties. The ultimate parent company is involved with manufacturing operations that are focused on producing generics, branded generics, speciality, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients and intermediates in the full range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

In 2021, Sun Pharma Global FZE (former Parent Company) had merged with the ultimate parent company. The Company is yet to obtain the certificate authorizing the registration of the transfer of shares to be approved by the Bureau of Internal Revenue (BIR).

On January 20, 2023, the Company's Board of Directors (BOD) approved the change in the Company's registered office address, which is also its principal place of business, from Unit 604, Liberty Center Building, 104 H.V. Dela Costa Street, Salcedo Village, Makati City to 17F Unit 3 Milestone @ Fifth Avenue, 5th Avenue Bonifacio Global City, Fort Bonifacio 1634 Taguig City NCR, Fourth District Philippines. The amendment was approved by the BIR on July 19, 2023 and by the SEC on August 8, 2023.

The registered office address of the ultimate parent company is located at Sun House CTS No. 201 B/1, Western Express Highway, Goregaon, Mumbai 400063, India. The registered office address of the new parent company is located at Polarisavenue 87, 2132 JH Hoofddorp, The Netherlands.

1.2 Status of Operations

The Company has reported substantial losses in the prior years, resulting in capital deficiency of P275.6 million and P335.3 million as at March 31, 2026 and 2025, respectively. This condition indicates the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern entity. In response to this matter, the Company's management launched its Primary Care division in the fourth quarter of FY2026 and added new molecules to its Oncology portfolio. Moreover, the Company is exploring opportunities to further expand its product portfolio with new molecules. The Company's management also continues to strengthen the strategy to expand its market to increase its sales and continuously generate profit by continuous intensive marketing of its products. Management is confident that the Company will be able to recover from losses in the next succeeding years.

The Company generated an operating income of P119.3 million and P35.1 million in 2026 and 2025, respectively. The Company's ultimate parent company has also committed to provide the Company with financial assistance to maintain it as going concern and enable it to meet its liabilities as and when they fall due until the next reporting period. Accordingly, the financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments to reflect possible future effects on the recoverability and classification of assets or the amount and classification of liabilities that might result from the outcome of this uncertainty.

1.3 Approval of Financial Statements

The financial statements of the Company as at and for the year ended March 31, 2026 (including the comparative financial statements as at and for the fiscal year ended March 31, 2025) were authorized for issue by the Company's BOD on May 18, 2026.

2. MATERIAL ACCOUNTING POLICY INFORMATION

The material accounting policy information that have been used in the preparation of these financial statements are summarized below and in the succeeding pages. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Basis of Preparation of Financial Statements

(a) Statement of Compliance with Philippine Financial Reporting Standards

The financial statements of the Company have been prepared in accordance with Philippine Financial Reporting Standards (PFRS Accounting Standards). PFRS Accounting Standards are adopted by the Financial and Sustainability Reporting Standards Council (FSRSC) from the pronouncements issued by the International Accounting Standards Board and approved by the Philippine Board of Accountancy.

The financial statements have been prepared using the measurement bases specified by PFRS Accounting Standards for each type of asset, liability, income and expense. The measurement bases are more fully described in the accounting policies that follow.

(b) *Presentation of Financial Statements*

The financial statements are presented in accordance with Philippine Accounting Standard (PAS) 1, *Presentation of Financial Statements*. The Company presents all items of income and expenses and other comprehensive income or loss in a single statement of comprehensive income.

The Company presents a third statement of financial position as at the beginning of the preceding period when it applies an accounting policy retrospectively, or makes a retrospective restatement or reclassification of items that has a material effect on the information in the statement of financial position at the beginning of the preceding period. The related notes to the third statement of financial position are not required to be disclosed.

(c) *Functional and Presentation Currency*

These financial statements are presented in Philippine pesos, the Company's functional and presentation currency, and all values represent absolute amounts except when otherwise indicated.

Items included in the financial statements of the Company are measured using its functional currency. Functional currency is the currency of the primary economic environment in which the Company operates.

2.2 Adoption of Amended PFRS Accounting Standards

(a) *Effective in 2025 that is Relevant to the Company*

The Company adopted for the first time amendments to PAS 21, *The Effects of Changes in Foreign Exchange Rates – Lack of Exchangeability*, which are mandatorily effective for annual periods beginning on or after January 1, 2025. The amendments require entities to assess whether a currency is exchangeable and to determine a spot exchange rate when exchangeability is lacking. These amendments also mandate the disclosure of information that enables users of financial statements to understand the impact of a currency not being exchangeable. The amendments had no significant impact on the financial statements of the Company.

(b) *Effective Subsequent to 2025 but not Adopted Early*

There are pronouncements effective for annual periods subsequent to 2025, which are adopted by the FSRSC. Management will adopt the following relevant pronouncements in accordance with their transitional provisions; and unless otherwise indicated, none of these are expected to have significant impact on the Company's financial statements:

- (i) PFRS 9 and PFRS 7 (Amendments), *Financial Instruments, and Financial Instruments: Disclosures – Amendments to the Classification and Measurement of Financial Instruments* (effective from January 1, 2026).
- (ii) PFRS 9 and PFRS 7 (Amendments), *Financial Instruments, and Financial Instruments Disclosures – Amendments to Contracts Referencing Nature-dependent Electricity* (effective January 1, 2026).

- (iii) PFRS 18, *Presentation and Disclosure in Financial Statements* (effective from January 1, 2027). The new standard impacts the classification of profit or loss items (i.e., into operating, investing and financing categories) and the presentation of subtotals in the statement of profit or loss (i.e., operating profit and profit before financing and income taxes). The new standard also changes the aggregation and disaggregation of information presented in the primary financial statements and in the notes. It also introduces required disclosures about management-defined performance measures. The new standard, however, does not affect how an entity recognizes and measures its financial condition, financial performance and cash flows.
- (iv) PFRS 19, *Subsidiaries without Public Accountability: Disclosures* (effective from January 1, 2027). The new standard reduces the disclosure requirements prescribed by other standards for subsidiaries without public accountability. It changes disclosure requirements prescribed by other standards as the reporting entity will instead refer to PFRS 19 for required disclosures.

2.3 Financial Instruments

(a) Financial Assets

Currently, all of the Company's financial assets are classified and measured at amortized cost.

The Company's financial assets at amortized cost are presented as Cash, Trade and Other Receivables (except for advances to suppliers, and advances to employees that are subject for liquidation) and Refundable deposits (presented as part of Other Assets) in the statement of financial position.

At the end of the reporting period, the Company assesses and recognizes allowance for expected credit losses (ECL) on its financial assets measured at amortized cost. Measurement of the ECL is determined by a probability-weighted estimate of credit losses over the expected life of the financial instruments evaluated based on a range of possible outcome.

The Company applies the simplified approach in measuring ECL, which uses a lifetime expected loss allowance for all trade and other receivables.

(b) Financial Liabilities

Financial liabilities include trade and other payables (except for return liability and tax-related liabilities), advances from parent company and lease liabilities are recognized when the Company becomes a party to the contractual terms of the instrument.

Advances from parent company were availed to finance working capital requirements.

2.4 Inventories

The cost of inventories is determined using the first-in, first-out method. Net realizable value of raw materials is the current replacement cost.

2.5 Property and Equipment

All property and equipment are stated at cost less accumulated depreciation, amortization, and any impairment in value, if any.

Depreciation is computed on the straight-line basis over the estimated useful lives of the assets as follows:

Furniture and fixtures	5 to 10 years
Vehicles	3 to 5 years
Office equipment	3 to 5 years

Leasehold improvements are amortized using the straight-line method over the estimated useful life or the remaining term of lease, whichever is shorter.

2.6 Revenue Recognition

The Company's main source of revenue comes from distribution on wholesale of pharmaceutical products to its customers wherein revenue is recognized as the control transfers at the point in time. This is generally when the customer has taken undisputed delivery of goods.

The significant judgement used in determining the timing of satisfaction of the Company's performance obligation with respect to sale of pharmaceutical products is disclosed in Note 3.1(a).

2.7 Leases – Company as Lessee

The Company amortizes the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset of five years or the end of the lease term, whichever is shorter.

The Company has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognizing a right-of-use asset and lease liability, the payments in relation to these are recognized as an expense in profit or loss on a straight-line basis over the lease term.

On the statement of financial position, right-of-use assets and lease liabilities have been presented separately from all other assets and liabilities, respectively.

3. SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES

The preparation of the Company's financial statements in accordance with PFRS Accounting Standards requires management to make judgments and estimates that affect the amounts reported in the financial statements and related notes. Judgments and estimates are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results may ultimately differ from these estimates.

3.1 Critical Management Judgments in Applying Accounting Policies

In the process of applying the Company's accounting policies, management has made the following judgment, apart from those involving estimations, which has the most significant effect on the amounts recognized in the financial statements:

(a) Determination of Timing of Satisfaction of Performance Obligations

Revenue comprises revenue from sale of pharmaceutical products.

The Company determines that its revenue from sale of goods shall be recognized at a point in time when the control of the goods has been transferred to the customer, i.e., generally when the customer has acknowledged delivery of the goods.

(b) Determination of ECL on Trade and Other Receivables

The Company uses a provision matrix to calculate ECL for trade and other receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns.

The provision matrix is based on the Company's historical observed default rates. The Company's management intends to regularly calibrate (i.e., on an annual basis) the matrix to consider the historical credit loss experience with forward-looking information (i.e., forecast economic conditions). Details about the ECL on the Company's trade and other receivables are disclosed in Note 19.3(b).

(c) Recognition of Provisions and Contingencies

Provisions are recognized when present obligations will probably lead to an outflow of economic resources and they can be estimated reliably even if the timing or amount of the outflow may still be uncertain. A present obligation arises from the presence of a legal or constructive obligation that has resulted from past events. Similarly, possible outflows of economic benefits to the Company that do not yet meet the recognition criteria of a liability are considered contingent liabilities, hence, are not recognized in the financial statements.

Judgment is exercised by management to distinguish between provisions and contingencies. Disclosures on relevant provisions and contingencies are presented in Note 18.

3.2 Key Sources of Estimation Uncertainty

Discussed below and in the succeeding pages are the key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

(a) Estimation of Allowance for ECL

The measurement of the allowance for ECL on financial assets at amortized cost is an area that requires the use of significant assumptions about the future economic conditions and credit behavior (e.g., likelihood of customers defaulting and the resulting losses). Explanation of the inputs, assumptions and estimation used in measuring ECL is further detailed in Note 19.3.

(b) Estimation of Amounts Involving Right of Return

The Company's contract of sale has variable consideration which is the right of return given to the customers within a specified period. Given the large number of contracts of the same characteristics, the Company considered the expected value method under the provisions of PFRS 15, *Revenue from Contracts with Customers*, which better predicts the amounts of consideration it will be required to return and receive involving the customer's right of return.

The carrying amount of the return liabilities as at March 31, 2026 and 2025 is presented as part of Trade and Other Payables account in the statements of financial position (see Note 10).

(c) Determination of Net Realizable Value of Inventories

In determining the net realizable value of inventories, management takes into account past experience and other factors affecting the net realizable value of inventory items. Future realization of the carrying amounts of inventories as presented in Note 6 is evaluated on a continuous basis throughout the year. Both aspects are considered key sources of estimation uncertainty and may cause significant adjustments to the Company's inventories within the next reporting period.

(d) Determination of Realizable Amount of Deferred Tax Assets (DTA)

The Company reviews its deferred tax assets at the end of each reporting period and reduces the carrying amount to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Management assessed that the deferred tax assets as at March 31, 2025 may not be fully utilized in the subsequent reporting periods. However, the management further assessed that certain deferred tax assets are realizable and therefore recognized as of March 31, 2026. The carrying value of deferred tax assets is disclosed in Note 15.

(e) Impairment of Non-financial Assets

The Company's property and equipment, right-of-use assets, and other non-financial assets are subject to impairment testing. All individual assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

In assessing impairment, management estimates the recoverable amount of each asset or a cash-generating unit based on expected future cash flows and uses an interest rate to calculate the present value of those cash flows. Estimation uncertainty relates to assumptions about future operating results and the determination of a suitable discount rate. Though management believes that the assumptions used in the estimation of fair values reflected in the financial statements are appropriate and reasonable, significant changes in these assumptions may materially affect the assessment of recoverable values and any resulting impairment loss could have a material adverse effect on the results of operations.

No impairment losses are necessary to be recognized in fiscal year 2026 and 2025 on the Company's property and equipment, right-of-use assets, and other non-financial assets based on the management's assessment (see Notes 8 and 9.1).

(f) *Estimation of Useful Lives of Property and Equipment and Right-of-use Asset*

The Company estimates the useful lives of property and equipment and right-of-use assets, based on the period over which the assets are expected to be available for use. The estimated useful lives of property and equipment and right-of-use asset are reviewed periodically and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence and legal or other limits on the use of the assets.

The carrying amounts of property and equipment and right-of-use assets are presented in Notes 8 and 9.1, respectively. Based on management's assessment as at March 31, 2026 and 2025, there is no change in estimated useful lives of those assets during those years. Actual results, however, may vary due to changes in estimates brought about by changes in factors mentioned above.

(g) *Valuation of Post-employment Benefit*

The determination of the Company's obligation and cost of post-employment defined benefit is dependent on the selection of certain assumptions used by actuaries in calculating such amounts. Those assumptions include, among others, discount rates and salary rate increase.

A significant change in any of these actuarial assumptions may generally affect the recognized expense, other comprehensive income or losses and the carrying amount of the post-employment benefit obligation in the next reporting period.

The amounts of post-employment benefit obligation and expense and an analysis of the movements in the estimated present value of retirement benefit obligation, as well as the significant assumptions used in estimating such obligation, are presented in Note 14.2.

4. CASH

This account includes the following:

<i>(Amounts in PHP)</i>	2026	2025
Cash in banks	135,876,908	150,119,884
Cash on hand	2,793,666	692,221
	<u>138,670,574</u>	<u>150,812,105</u>

Cash in banks generally earn interest based on daily bank deposit rates. Interest earned from cash in bank is reported as part of Interest income under Other Charges – net account in the statements of comprehensive income (see Note 13).

5. TRADE AND OTHER RECEIVABLES

This account is composed of the following:

<i>(Amounts in PHP)</i>	<u>Note</u>	<u>2026</u>	<u>2025</u>
Trade receivables		399,381,418	269,986,303
Advances to employees		-	121,879
Others	16.3	18,392	2,677,633
		399,399,810	272,785,815
Allowance for impairment		(25,857,656)	(11,260,645)
		373,542,154	261,525,170

Trade receivables have contractual terms of 30, 60, 90 or 120 days and do not bear any interest.

Advances to employees includes salary advances and salary loans granted to certain employees. Salary loans are subject to an annual interest rate of 12%. Interest income earned in fiscal year 2025 from salary loans is recognized as part of Interest income under Other Charges – net account in the 2025 statement of comprehensive income (see Note 13). There was no similar transaction in fiscal year 2026.

All of the Company's trade and other receivables have been reviewed for impairment [see Note 19.3(b)]. Certain trade receivables were found to be impaired; hence, adequate amount of allowance for impairment has been recognized.

A reconciliation of the allowance for impairment at the beginning and end of fiscal year 2026 and 2025 is shown below.

<i>(Amounts in PHP)</i>	<u>Note</u>	<u>2026</u>	<u>2025</u>
Balance at beginning of year		11,260,645	8,205,440
Impairment loss	13	14,597,011	3,055,205
Balance at end of year		25,857,656	11,260,645

The net carrying value of trade and other receivables is considered a reasonable approximation of fair value.

6. INVENTORIES

The details of inventories as at March 31 are as follows:

<i>(Amounts in PHP)</i>	<u>2026</u>	<u>2025</u>
Finished goods –		
At cost	262,346,386	197,610,744
At net realizable value		
Cost	262,346,386	197,610,744
Allowance for impairment	(53,742,364)	(48,788,400)
	208,604,022	148,822,344
	208,604,022	148,822,344

Movements in allowance for inventory obsolescence consist of:

<i>(Amounts in PHP)</i>	<u>Note</u>	<u>2026</u>	<u>2025</u>
Balance at beginning of year		48,788,400	53,844,360
Loss on inventory obsolescence	12	14,199,291	12,366,863
Inventory write-off		<u>(9,245,327)</u>	<u>(17,422,823)</u>
Balance at the end of the year		<u>53,742,364</u>	<u>48,788,400</u>

The Company disposed obsolete sample inventories amounting to P9.2 million and P17.4 million in fiscal year 2026 and 2025, respectively. These were directly written-off and presented as Inventory write-off under Selling and Administrative Expenses account in the statements of comprehensive income.

The loss on inventory obsolescence, net of reversal of allowance, is included in the Selling and administrative expenses account in the statements of comprehensive income (see Note 12).

7. OTHER ASSETS

This account composed of the following:

<i>(Amounts in PHP)</i>	<u>2026</u>	<u>2025</u>
Current:		
Input value-added tax (VAT)	18,108,524	14,770,782
Short-term investments	10,000,000	-
Advances to suppliers	2,732,002	16,006,608
Prepaid expenses	1,884,774	34,526
Deferred input VAT	<u>817,301</u>	<u>1,345,975</u>
	<u>33,542,601</u>	<u>32,157,891</u>
Non-current –		
Refundable deposits	<u>7,628,985</u>	<u>2,907,149</u>

Short-term investments represent a 180-day time deposit entered by the Company in fiscal year 2026 subject to a 3.625% annual interest rate. There was no similar transaction in fiscal year 2025.

Prepaid expenses include prepayments for advertising, insurance, and supplies availed of by the Company.

Refundable deposits pertains to deposit for leases entered by the Company and deposits for fleet cards.

8. PROPERTY AND EQUIPMENT

The gross carrying amounts and accumulated depreciation of property and equipment at the beginning and end of 2026 and 2025 are shown below.

<i>(Amounts in PHP)</i>	<u>Vehicle</u>	<u>Furniture and Fixtures</u>	<u>Office Equipment</u>	<u>Leasehold Improvements</u>	<u>Total</u>
March 31, 2026					
Cost	76,838,411	103,081	7,102,659	17,736,439	101,780,590
Accumulated depreciation and amortization	(34,713,256)	(99,993)	(4,018,699)	(9,494,547)	(48,326,495)
Net carrying amount	<u>42,125,155</u>	<u>3,088</u>	<u>3,083,960</u>	<u>8,241,892</u>	<u>53,454,095</u>
March 31, 2025					
Cost	66,092,393	103,081	5,164,797	17,105,189	88,465,460
Accumulated depreciation and amortization	(29,195,702)	(84,011)	(3,053,847)	(5,635,341)	(37,968,901)
Net carrying amount	<u>36,896,691</u>	<u>19,070</u>	<u>2,110,950</u>	<u>11,469,848</u>	<u>50,496,559</u>
April 1, 2024					
Cost	56,050,993	103,081	4,542,480	16,264,409	76,960,963
Accumulated depreciation	(24,993,865)	(67,376)	(2,136,186)	(2,368,447)	(29,565,874)
Net carrying amount	<u>31,057,128</u>	<u>35,705</u>	<u>2,406,294</u>	<u>13,895,962</u>	<u>47,395,089</u>

A reconciliation of the carrying amounts of property and equipment at the beginning and end of 2026 and 2025 is shown below.

<i>(Amounts in PHP)</i>	<u>Vehicle</u>	<u>Furniture and Fixtures</u>	<u>Office Equipment</u>	<u>Leasehold Improvements</u>	<u>Total</u>
Balance at April 1, 2025, net of accumulated depreciation and amortization	36,896,691	19,070	2,110,950	11,469,848	50,496,559
Additions	17,672,320	-	1,937,862	631,250	20,241,432
Depreciation charges for the year	(12,443,856)	(15,982)	(964,852)	(3,859,206)	(17,283,896)
Balance at March 31, 2026, net of accumulated depreciation and amortization	<u>42,125,155</u>	<u>3,088</u>	<u>3,083,960</u>	<u>8,241,892</u>	<u>53,454,095</u>
Balance at April 1, 2024 net of accumulated depreciation and amortization	31,057,128	35,705	2,406,294	13,895,962	47,395,089
Additions	16,730,268	-	622,317	840,780	18,193,365
Depreciation charges for the year	(10,890,705)	(16,635)	(917,661)	(3,266,894)	(15,091,895)
Balance at March 31, 2025 net accumulated depreciation and amortization	<u>36,896,691</u>	<u>19,070</u>	<u>2,110,950</u>	<u>11,469,848</u>	<u>50,496,559</u>

The amount of depreciation charges in fiscal year 2026 and 2025 is presented as part of Depreciation and amortization under Selling and Administrative Expenses in the statements of comprehensive income (see Note 12).

In fiscal years 2026 and 2025, the Company sold fully depreciated property and equipment amounting to P0.4 million and P1.0 million, respectively. The gain on disposals of these property and equipment are presented as Gain on disposals of assets under Other Charges – net account in the statements of comprehensive income (see Note 13).

As at March 31, 2026 and 2025, the gross carrying amount of the Company's fully depreciated property and equipment that are still used in operation amounted to P1.6 million and 5.9 million, respectively. In fiscal years 2026 and 2025, the Company retired some of its fully depreciated property and equipment amounting to P6.9 million and P5.2 million, respectively.

9. LEASES

The Company has leases for certain office spaces and vehicles. Each lease is reflected on the statements of financial position as Right-of-Use Assets and Lease Liabilities.

Each lease generally imposes a restriction that, unless there is a contractual right for the Company to sub-lease the asset to another party, the right-of-use assets can only be used by the Company. The lease is either non-cancellable or may only be cancelled by incurring a substantive termination fee. The Company is prohibited from selling or pledging the underlying leased assets as security and they must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. Further, the Company must ensure the leased assets and incur maintenance fees on such items in accordance with the lease contracts.

The table below describes the nature of the Company's right-of-use assets recognized in the statements of financial position.

	2026	2025
Number of right-of-use assets leased	32	1
Range of remaining term	3 - 5 years	3 years
Average remaining lease term	4 years	3 years
Number of leases with extension options	32	1

9.1 Right-of-use Assets

The carrying amount of the Company's right-of-use assets as at March 31, 2026 and 2025 and the movements in each year are shown below.

(Amounts in PHP)	Note	2026	2025
Balance at beginning of year		23,488,822	31,318,429
Additions		29,077,911	-
Amortization for the year	12	(8,798,871)	(7,829,607)
Balance at the end of the year		<u>43,767,862</u>	<u>23,488,822</u>

9.2 Lease Liabilities

Lease liabilities presented in the statement of financial position as at March 31 are as follows:

(Amounts in PHP)	2026	2025
Current	16,565,280	7,762,844
Non-current	<u>30,203,728</u>	<u>17,691,096</u>
Balance at end of year	<u>46,769,008</u>	<u>25,453,940</u>

A reconciliation of the carrying amount of the Company's lease liabilities at the beginning and end of fiscal year 2026 and 2025 is shown below.

<i>(Amounts in PHP)</i>	2026	2025
Balance at beginning of year	25,453,940	33,082,683
Additions	29,077,911	-
Payments	(7,977,106)	(7,911,180)
Amortization of interest	214,263	282,437
Balance at end of year	46,769,008	25,453,940

Amortization of interest is recognized under Selling and Administrative Expense account in the statements of comprehensive income (see Note 12). The lease liabilities are secured by the related underlying asset (see Note 9.1).

The undiscounted maturity analysis of lease liabilities is as follows:

<i>(Amounts in PHP)</i>	Within one year	One to five years	Total
March 31, 2026			
Lease payment	18,419,910	32,268,358	50,688,268
Interest	(1,854,630)	(2,064,630)	(3,919,260)
	16,565,280	30,203,728	46,769,008
March 31, 2025			
Lease payment	7,977,107	17,880,272	25,857,379
Interest	(214,263)	(189,176)	(403,439)
	7,762,844	17,691,096	25,453,940

9.3 Lease Payments Not Recognized as Liabilities

The Company has elected not to recognize a lease liability for short-term leases. Payments made under such leases are expensed on a straight-line basis.

In fiscal year 2026 and 2025, expenses relating to these leases amounted to P1.8 million and P2.3 million, respectively, and is presented as Rentals under Selling and Administrative Expense account in the statements of comprehensive income (see Note 12). As at March 31, 2026 and 2025, the Company has not committed to short-term leases.

9.4 Additional Profit or Loss and Cash Flow Information

The total cash outflow in respect of leases amounted to P8.0 million and P7.9 million in fiscal year 2026 and 2025, respectively. Interest expense in relation to lease liabilities amounted to P0.2 million and P0.3 million in fiscal year 2026 and 2025, respectively, and is presented under Selling and Administrative Expense account in the statements of comprehensive income (see Note 12).

10. TRADE AND OTHER PAYABLES

This account consists of the following:

<i>(Amounts in PHP)</i>	<u>Note</u>	<u>2026</u>	<u>2025</u>
Trade payables			
Related party	16.1	693,434,623	533,546,061
Others		18,432,829	16,931,174
		711,867,452	550,477,235
Other payables:			
Accrued expenses		29,578,760	59,352,298
Return liabilities		2,703,735	4,701,072
Payable to government		2,384,019	3,751,286
Advances from customers		-	25,515,000
Salaries and wages payable		-	4,903,905
Other payable		673,032	1,902,804
		35,339,546	100,126,365
		747,206,998	650,603,600

Accrued expenses include the Company's obligations relating to the accrual of expense related to reimbursements of sales agent, storage fees, utilities, professional fees and other expenses.

11. REVENUES

The Company derived revenues from the transfer of goods at a point in time.

<i>(Amounts in PHP)</i>	<u>2026</u>	<u>2025</u>
Sales, net of trade discounts	835,792,361	656,067,436
Sales returns and allowances	(1,649,570)	(3,433,614)
	834,142,791	652,633,822

A summary of additional disaggregation from the revenues are shown below.

<i>(Amounts in PHP)</i>	<u>2026</u>	<u>2025</u>
Oncology drugs	327,219,347	298,517,221
Central nervous system drugs	313,003,359	305,085,501
Dermatology	69,381,943	25,447,401
Ophthalmology	23,525,467	20,010,568
Primary Care	12,093,974	-
Others	88,918,701	3,573,131
	834,142,791	652,633,822

12. OPERATING EXPENSES BY NATURE

The Company's operating expenses are as follows:

<i>(Amounts in PHP)</i>	Notes	2026	2025
Net purchases	16.1	203,200,825	218,741,151
Selling and distribution		166,715,822	174,054,941
Salaries and employee benefits	14, 16.4	150,664,185	94,880,588
Change in inventories	6	59,781,678	24,408,303
Transportation and travel		31,201,587	16,536,747
Depreciation and amortization	8, 9.1	26,082,768	22,945,501
Professional fees		18,367,132	16,886,025
Loss on inventory obsolescence – net of reversal	6	14,199,291	12,366,863
Input VAT on exempt sales		13,478,000	5,053,857
Insurance		9,901,981	7,692,418
Communications		6,495,087	4,687,102
Repairs and maintenance		2,430,008	2,263,716
Taxes and licenses		2,395,849	2,971,974
Rentals	9.3	1,762,374	2,311,267
Recruitment expense		1,202,956	4,925,403
Utilities		315,421	347,854
Product license & registration		-	1,873,683
Office supplies		-	1,861,782
Others	9.2, 14.2	6,607,183	2,696,555
		714,802,147	617,505,730

Others include bank charges, registration fees, interest expense from lease liabilities and retirement benefit obligation, and other miscellaneous expenses.

These expenses are classified in the statements of comprehensive income as follows:

<i>(Amounts in PHP)</i>	2026	2025
Cost of goods sold	277,226,055	243,149,454
Selling and administrative expenses	437,576,092	374,356,276
	714,802,147	617,505,730

13. OTHER INCOME (CHARGES) – Net

This account consists of:

<i>(Amounts in PHP)</i>	<u>Notes</u>	<u>2026</u>	<u>2025</u>
Other income:			
Gain on disposal of assets	8	408,837	982,515
Interest income	4, 5	73,290	99,240
		<u>482,127</u>	<u>1,081,755</u>
Other charges:			
Foreign exchange loss	16.1, 16.2	(59,437,425)	(10,472,204)
Impairment loss on trade and other receivables	5	(14,597,011)	(3,055,205)
Realized foreign exchange gain (loss)		10,189,793	(9,134,428)
		<u>(63,844,643)</u>	<u>(22,661,837)</u>
		<u>(63,362,516)</u>	<u>(21,580,082)</u>

14. EMPLOYEE BENEFITS

14.1 Salaries and Employee Benefits

Expenses recognized for salaries and employee benefits are presented below.

<i>(Amounts in PHP)</i>	<u>Notes</u>	<u>2026</u>	<u>2025</u>
Short-term employee benefits		148,506,237	93,623,612
Post-employment defined benefits	14.2	2,157,948	1,256,976
	12, 16.4	<u>150,664,185</u>	<u>94,880,588</u>

14.2 Post-employment Benefit

(a) Characteristics of the Defined Benefit Plan

The Company does not have an established retirement benefit plan and only conforms to the minimum regulatory benefit under the Republic Act No. 7641 *Retirement Pay Law*, which is of the final salary defined benefit type and provides retirement benefit equal to 22.5 day pay for every year of credited service. The regulatory benefit is paid in a lump sum upon retirement.

In accordance with the provisions of the Labor Code, the Company is required to pay eligible employees at least the minimum regulatory benefit upon retirement, subject to age and service requirements. Since the Company does not have any formal, trusted retirement plan, there are no Trustees yet. Moreover, there are no unusual or significant risk to which the retirement obligation exposes the Company. However, it should be noted that in the event a benefit claim arises under the retirement obligation, the benefit shall immediately be due and payable from the Company.

In fiscal year 2026 and 2025, the Company engaged an independent actuary to determine the valuation of its retirement obligation.

(b) *Explanation of Amounts Presented in the Financial Statements*

All amounts presented below are based on the actuarial valuation report obtained from an independent actuary.

The movements in the present value of the post-employment benefit obligation recognized in the books are as follows:

<i>(Amounts in PHP)</i>	<u>2026</u>	<u>2025</u>
Balance at beginning of year	5,979,988	4,715,751
Current service cost	2,157,948	1,256,976
Interest expense	378,533	295,206
Remeasurements –		
Actuarial losses (gains) arising from:		
Experience adjustments	1,292,859	(238,747)
Changes in financial assumptions	<u>(707,074)</u>	<u>(49,198)</u>
Balance at end of year	<u><u>9,102,254</u></u>	<u><u>5,979,988</u></u>

The components of amounts recognized in profit or loss and in other comprehensive loss in respect of the defined benefit post-employment plan are as follows:

<i>(Amounts in PHP)</i>	<u>2026</u>	<u>2025</u>
<i>Reported in profit or loss:</i>		
Current service cost	2,157,948	1,256,976
Interest expense	<u>378,533</u>	<u>295,206</u>
	<u><u>2,536,481</u></u>	<u><u>1,552,182</u></u>
<i>Reported in other comprehensive income (loss) –</i>		
Actuarial losses (gains) arising from:		
Experience adjustments	1,292,859	(238,747)
Changes in financial assumptions	<u>(707,074)</u>	<u>(49,198)</u>
	<u><u>585,785</u></u>	<u><u>(287,945)</u></u>

Current service cost is presented as part of Salaries and employee benefits, while the interest expense is recognized as part of Others both under Selling and Administrative Expense account in the statements of comprehensive income (see Note 12).

Amounts recognized in other comprehensive loss are considered as items that will not be reclassified subsequently to profit or loss.

In determining the amounts of the defined benefit post-employment obligation as at March 31, 2026 and 2025, the following significant actuarial assumptions were used:

	<u>2026</u>	<u>2025</u>
Discount rate	7.07%	6.33%
Expected rate of salary increases	5.00%	5.00%

Assumptions regarding future mortality experience are based on published statistics and mortality tables. The average remaining working lives of an individual retiring at the age of 60 is 19.8 years for both males and females. These assumptions were developed by management with the assistance of an independent actuary. Discount factors are determined close to the end of each reporting period by reference to the interest rates of a zero-coupon government bond with terms to maturity approximating to the terms of the post-employment benefit obligation. Other assumptions are based on current actuarial benchmarks and management's historical experience.

(c) *Risks Associated with the Retirement Plan*

The plan exposes the Company to actuarial risks such as interest rate risk, longevity risk and salary risk.

(i) *Interest Rate Risk*

The present value of the defined benefit obligation is calculated using a discount rate determined by reference to market yields of government bonds. Generally, a decrease in the interest rate of a reference government bonds will increase the retirement obligation.

(ii) *Longevity and Salary Risks*

The present value of the defined benefit obligation is calculated by reference to the best estimate of the mortality of the plan participants during their employment and to their future salaries. Consequently, increases in the life expectancy and salary of the plan participants will result in an increase in the plan obligation.

(d) *Other Information*

The information on the sensitivity analysis for certain significant actuarial assumptions and the timing and uncertainty of future cash flows related to the retirement plan are discussed in the succeeding page.

(i) *Sensitivity Analysis*

The table below summarize the effects of changes in the significant actuarial assumptions used in the determination of the defined benefit obligation:

<i>(Amounts in PHP)</i>	Impact on Post-employment Benefit Obligation		
	Change in assumption	Increase in assumption	Decrease in assumption
<u>March 31, 2026</u>			
Discount rate	+/-1%	(856,096)	971,953
Salary growth rate	+/-1%	879,779	(982,419)
<u>March 31, 2025</u>			
Discount rate	+/-1%	(651,647)	752,626
Salary growth rate	+/-1%	665,215	(755,140)

(ii) *Funding Arrangements and Expected Contributions*

The plan is currently unfunded based on the latest actuarial valuation. While there are no minimum funding requirement in the country, the size of the underfunding may pose a cash flow risk in about ten years' time when a significant number of employees is expected to retire.

The undiscounted expected benefit payments amounting to P0.3 million and P20.6 million from the plan are expected to be realized within five years and six years to ten years, respectively

The weighted average duration of the defined benefit obligation at the end of the reporting period is 10 years.

15. TAXES

The components of tax expense as reported in profit or loss follow:

<i>(Amounts in PHP)</i>	2026	2025
<i>Reported in profit or loss:</i>		
Regular corporate income tax (RCIT)	34,009,971	9,190,412
Final tax at 20%	14,658	17,093
	34,024,629	9,207,505
Deferred tax income arising from origination and reversal of temporary differences	(38,207,565)	-
	(4,182,936)	9,207,505
<i>Reported in other comprehensive income or loss –</i>		
Deferred tax income arising from origination and reversal or temporary differences	(146,446)	-

A reconciliation of tax on pretax profit computed at the applicable statutory rates to tax expense reported in profit or loss follows:

<i>(Amount in PHP)</i>	<u>2026</u>	<u>2025</u>
Tax on pretax profit at 25%	13,994,532	3,387,003
Adjustment for income subjected to lower income tax rate	(3,665)	(4,273)
Tax effect of:		
Recognized deferred tax asset on other temporary differences	(38,207,565)	-
Non-deductible expenses	20,033,762	2,749,801
Unrecognized deferred tax asset on other temporary differences	<u>-</u>	<u>3,074,974</u>
Tax expense (income)	<u>(4,182,936)</u>	<u>9,207,505</u>

As at March 31, 2025, the Company has not recognized DTA related to the items as presented below. However, in fiscal year 2026, the Company assessed that sufficient taxable profit will be available to allow part of the DTA to be utilized in the succeeding years. Hence, certain unrecognized DTA in the previous years were already recognized in the current fiscal year.

<i>(Amount in PHP)</i>	<u>Tax Base</u>		<u>Tax Effect</u>	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
<u>Profit or Loss</u>				
Allowance for inventory obsolescence	53,742,364	48,788,400	13,435,591	12,197,100
PFRS 16	2,572,620	1,965,118	643,155	491,279
Unrealized foreign exchange loss	59,437,425	28,333,938	14,859,356	7,083,481
Allowance for impairment loss	25,857,656	11,260,645	6,464,414	2,815,161
Retirement benefit obligation	8,516,461	6,001,693	2,129,115	1,500,423
Return liabilities	<u>2,703,735</u>	<u>4,701,072</u>	<u>675,934</u>	<u>1,175,268</u>
	152,830,261	101,050,866	38,207,565	25,262,716
<u>Other Comprehensive Income</u>				
Retirement benefit obligation	<u>585,785</u>	<u>21,713</u>	<u>146,446</u>	<u>5,428</u>
Deferred tax asset	<u>153,416,046</u>	<u>101,072,579</u>	<u>38,354,011</u>	<u>25,268,144</u>

In 2026 and 2025, the Company is subject to MCIT which is computed at 2% of gross income, as defined under the tax regulations, or to RCIT, whichever is higher. In 2026 and 2025, the Company recognized RCIT as the RCIT is higher than the MCIT.

In fiscal year 2026 and 2025, the Company opted to continue claiming itemized deductions.

16. RELATED PARTY TRANSACTIONS

The Company has transactions with its parent company and previous related parties under common ownership as described below and in the succeeding page.

<i>(Amounts in PHP)</i>		<u>2026</u>		<u>2025</u>	
		<u>Amount of Transaction</u>	<u>Outstanding Balance</u>	<u>Amount of Transaction</u>	<u>Outstanding Balance</u>
Ultimate Parent Company –					
Purchase of inventories	16.1	249,322,730	(610,278,051)	14,141,330	(533,546,061)
Advances granted	16.2	-	18,392	-	18,392
Parent Company –					
Advances obtained – foreign exchange adjustments	16.2	18,772,988	(341,490,675)	6,872,556	(322,717,687)

Related Party Category	Note	2026		2025	
		Amount of Transaction	Outstanding Balance	Amount of Transaction	Outstanding Balance
Related Party Under Common Control –					
Distribution of samples	16.3	-	-	2,656,969	2,638,577
Purchase of inventories	16.1	87,530,133	(83,156,572)	-	-
Key management personnel –					
Compensation	16.4	(36,411,612)	-	(13,360,403)	-

16.1 Purchase Inventories

The Company purchases from its ultimate parent company and certain related party under common control of inventories sold to its distributors and product samples distributed to sales representatives as part of the Company's marketing and promotional activities (see Note 12). The related outstanding payables are presented as part of Trade payables under Trade and Other Payables account in the statements of financial position (see Note 10). The payables are generally unsecured, noninterest-bearing, and payable in cash within three months.

In fiscal year 2026 and 2025, the Company recognized unrealized loss amounting to P44.7 million and P13.6 million, respectively, related to outstanding trade payable from these transactions, which is presented as part of Foreign exchange loss under Other Charges - net account in the statements of comprehensive income (see Note 13).

16.2 Advances to/from Parent Company

The Company obtained advances from former parent company that are unsecured, noninterest-bearing and payable on demand or through offsetting arrangements. The advances were used to finance working capital requirements of the Company.

On July 1, 2021, the former parent company assigned to Sun Pharma (Netherlands) B.V. all its rights, title, interest, and benefits in and to the outstanding advances from former Parent Company.

The analysis of advances, presented as Advances from Parent Company in the statements of financial position, is shown below.

(Amounts in PHP)	Note	2026	2025
Balance at beginning of year		322,717,687	315,845,131
Cash flows from a non-cash financing activity – Unrealized foreign exchange loss	13	18,772,988	6,872,556
Balance at end of year		341,490,675	322,717,687

16.3 Distribution of Samples

In fiscal year 2025, the Company distributed samples to a related party under common control as part of their intensive marketing strategy. The related outstanding receivables from the distribution of samples to a related party are presented as part of Other receivables under Trade and Other Receivables accounts in the 2025 statement of financial position (see Note 5). There was no similar transaction in fiscal year 2026.

16.4 Key Management Personnel Compensation

Compensation of key management in fiscal year 2026 and 2025, representing short-term employee benefits, amounted to P36.4 million and P13.4 million, respectively, shown as part of Salaries and Employee Benefits under Selling and Administrative Expenses in the statements of comprehensive income (see Notes 12 and 14).

17. CAPITAL STOCK

The Company's authorized capital stock is P10.0 million divided into 100,000 shares at P100 par value per share. The Company's subscribed and outstanding capital stock as at March 31, 2026 and 2025 amounted to P8.7 million divided into 86,534 shares at P100 par value per share.

As at March 31, 2026 and 2025, the Company has only one stockholder owning 100 or more shares of the Company's capital stock.

18. COMMITMENTS AND CONTINGENCIES

There are other commitments and contingent liabilities that arise in the normal course of the Company's operations which are not reflected in the financial statements. Management believes that losses, if any, that may arise from these contingencies will not have any material effect on the financial statements.

19. RISK MANAGEMENT OBJECTIVES AND POLICIES

The Company is exposed to a variety of financial risks in relation to financial instruments. The main types of risks are interest rate risk, foreign currency risk, credit risk and liquidity risk.

The Company's risk management is coordinated with its parent company, in close cooperation with the Company's BOD, and focuses on securing the Company's short to medium-term cash flows by minimizing the exposure to financial markets.

The Company does not engage in the trading of financial assets for speculative purposes nor does it write options. The relevant financial risks to which the Company is exposed to are described below and in the succeeding pages.

19.1 Interest Rate Risk

As at March 31, 2026 and 2025, the Company has limited exposure to changes in market interest rates through its cash in bank. This financial instrument has shown small or measured changes in interest rates. Advances to employees have fixed interest rate.

19.2 Foreign Currency Risk

Most of the Company's transactions are carried out in Philippine pesos, its functional currency. Exposures to currency exchange rates arise from the Company's overseas advances, sales and purchases, which are primarily denominated in U.S. dollar and Euro exchange rates.

To mitigate the Company's exposure to foreign currency risk, non-Philippine peso cash flows are monitored.

Foreign currency-denominated financial assets and liabilities, translated into Philippine pesos at the closing rate follow:

(Amount in PHP)	2026		2025	
	U.S. Dollar	Euro	U.S. Dollar	Euro
Financial assets	18,392	-	2,656,969	-
Financial liabilities	(1,032,592,864)	(2,332,435)	(856,263,748)	(1,105,733)
	<u>(1,032,574,472)</u>	<u>(2,332,435)</u>	<u>(853,606,779)</u>	<u>(1,105,733)</u>

The table below illustrates the sensitivity of the Company's income before tax with respect to changes in Philippine peso against U.S. exchange rate. The percentage changes in rates have been determined based on the average market volatility in exchange rates, using standard deviation, in the previous 12 months at a 68% confidence level.

	2026			2025		
	Reasonably possible change in rate	Effect in income before tax	Effect in capital deficiency after tax	Reasonably possible change in rate	Effect in income before tax	Effect in capital deficiency after tax
PhP - USD	+/- 6.12%	63,157,437	(47,368,078)	+/-5.62%	48,122,023	(36,091,517)
PhP - Euro	+/-29.02%	676,769	(507,577)	+/-10.71%	118,410	(88,807)

Exposures to foreign exchange rates vary during the year depending on the volume of foreign currency denominated transactions. Nonetheless, the analysis above is considered to be representative of the Company's currency risk.

19.3 Credit Risk

Credit risk is the risk that a counterparty may fail to discharge an obligation to the Company. The Company is exposed to this risk for various financial instruments arising from selling goods and services to customers including related parties and placing deposits with banks.

The maximum credit risk exposure of financial assets is the carrying amount of the financial assets as shown on the face of the statement of financial position (or in the detailed analysis provided in the notes to the financial statements), as summarized in the succeeding page.

<i>Amounts in PHP</i>	Notes	2026	2025
Cash in banks	4	135,876,908	150,119,884
Trade and other receivables – net	5	373,542,154	261,382,627
Refundable deposits	7	7,628,985	2,907,149
		517,048,047	414,409,660

The Company continuously monitors defaults of customers identified individually and incorporate this information into its credit risk controls. The Company's policy is to deal only with creditworthy counterparties.

(a) *Cash in Banks*

The credit risk for cash is considered negligible since the counterparties are reputable banks with high quality external credit ratings. Included in cash are cash in banks which are insured by the Philippine Deposit Insurance Corporation up to a maximum coverage of P1.0 million for every depositor per banking institution.

(b) *Trade and Other Receivables*

The Company applies the simplified approach in measuring ECL, which uses a lifetime expected credit loss allowance for all trade and other receivables.

To measure the ECL, trade and other receivables have been grouped based on shared credit risk characteristics and the days past due (age buckets). The other receivables relate to receivables from both third and related parties other than trade receivables and have substantially the same risk characteristics as the trade receivables. The Company has therefore concluded that the expected loss rates for trade receivables are a reasonable approximation of the loss rates for the other assets.

The expected loss rates are based on the provision matrix as determined by management. The loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. In 2026 and 2025, the Company has identified inflation in the Philippines to be the most relevant factor and accordingly adjusts the historical loss rates based on expected changes in this factor.

On that basis, the loss allowance as at March 31, 2026 and 2025 was determined based on days past due, as follows for both trade and other receivables:

<i>(Amounts in PHP)</i>	Not more than 180 days	181 to 360 days	Over 360 days	Total
March 31, 2026				
Expected loss rates	0%	1.04%	100%	
Gross carrying amount:				
Trade receivables	292,120,801	82,256,969	24,680,459	399,058,229
Other receivables	-	-	-	-
Loss allowance	-	854,008	24,680,459	25,534,467
March 31, 2025				
Expected loss rates	0%	0%	100%	
Gross carrying amount:				
Trade receivables	190,048,890	68,676,767	11,260,645	269,986,302
Other receivables	2,656,969	-	-	2,656,969
Loss allowance	-	-	11,260,645	11,260,645

(c) *Refundable Deposits*

In respect of refundable deposits, the Company is not exposed to any significant credit risk exposure to any single counterparty or any group of counterparties having similar characteristics. Based on historical information, management consider the credit quality of refundable deposit to be good.

None of the financial assets are secured by collateral or other credit enhancements aside from cash in banks.

19.4 Liquidity Risk

The Company manages its liquidity needs by carefully monitoring cash outflows due in a day-to-day business. Liquidity needs are monitored in various time bands, on a day-to-day and week-to-week basis, as well as on the basis of a rolling 30-day projection. Long-term liquidity needs for a six-month and one-year period are identified monthly.

The Company maintains cash to meet its liquidity requirements for up to 45-day periods.

As at March 31, the Company's financial liabilities have contractual maturities which are presented below.

(Amounts in PHP)

	Due Within One Year	Due Beyond One Year	Total
<u>March 31, 2026</u>			
Trade and other payables*	744,822,979	-	744,822,979
Advances from the parent company	341,490,675	-	341,490,675
Lease liabilities	16,565,280	30,203,728	46,769,008
	<u>1,102,878,934</u>	<u>30,203,728</u>	<u>1,133,082,662</u>
<u>March 31, 2025</u>			
Trade and other payables	621,112,717	-	621,112,717
Advances from the parent company	322,717,687	-	322,717,687
Lease liabilities	7,762,844	17,691,096	25,453,940
	<u>951,807,511</u>	<u>20,517,332</u>	<u>972,324,843</u>

*Excluding government liabilities

20. CATEGORIES AND OFFSETTING OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES

20.1 Carrying Amounts and Fair Value by Category

The Company's financial assets and financial liabilities carried at amortized cost as presented in the statements of financial position are short-term in nature. Since the carrying value of the financial assets and liabilities approximate or are equal their fair values, a comparison between these values is no longer presented.

A description of the Company's risk management objectives and policies for financial instruments is provided in Note 19.

20.2 Offsetting of Financial Assets and Financial Liabilities

The Company has not set-off financial instruments in 2026 and 2025 and does not have relevant offsetting arrangements. Currently, financial assets and financial liabilities are settled on a gross basis.

21. FAIR VALUE MEASUREMENT AND DISCLOSURES

21.1 Fair Value Hierarchy

In accordance with PFRS 13, *Fair Value Measurement*, the fair value of financial assets and financial liabilities and non-financial assets which are measured at fair value on a recurring or non-recurring basis and those financial assets and financial liabilities not measured at fair value but for which fair value is disclosed in accordance with other relevant PFRS Accounting Standards, are categorized into three levels based on the significance of inputs used to measure the fair value.

The levels of fair value hierarchy is discussed below.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that an entity can access at the measurement date;
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and,
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level within which the asset or liability is classified is determined based on the lowest level of significant input to the fair value measurement.

For purposes of determining the market value at Level 1, a market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.

For investments which do not have quoted market price, the fair value is determined by using generally acceptable pricing models and valuation techniques or by reference to the current market of another instrument which is substantially the same after taking into account the related credit risk of counterparties, or is calculated based on the expected cash flows of the underlying net asset base of the instrument.

When the Company uses valuation technique, it maximizes the use of observable market data where it is available and relies as little as possible on entity specific estimates. If all significant inputs required to determine the fair value of an instrument are observable, the instrument is included in Level 2. Otherwise, it is included in Level 3.

21.2 Financial Instruments Measurement at Amortized Cost for which Fair Value is Disclosed

The carrying values of the Company's financial assets and financial liabilities approximate their fair values as at the end of the reporting period (see Note 20.1). Among the financial assets and financial liabilities of the Company, only cash is classified as Level 1 under fair value hierarchy, while the rest are Level 3.

22. CAPITAL MANAGEMENT OBJECTIVES, POLICIES AND PROCEDURES

The Company's capital management objectives are to ensure the Company's ability to continue as a going concern and to provide an adequate return to shareholders by pricing products and services commensurate with the level of risk.

The Company monitors capital on the basis of the carrying amount of equity as presented on the face of the statement of financial position.

The Company sets the amount of capital in proportion to its overall financing structure, i.e., equity and liabilities. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, issue new shares or sell assets to reduce debt.

The Company's total capital deficiency as at March 31, 2026 and 2025 amounted to P275.6 million and P335.3 million, respectively.

23. SUPPLEMENTARY INFORMATION REQUIRED BY THE BUREAU OF INTERNAL REVENUE

23.1 Requirements Under Revenue Regulations (RR) No. 15-2010

Presented below and in the succeeding pages is the supplementary information which is required by the BIR RR No. 15-2010 to be disclosed as part of the notes to financial statements. This supplementary information is not a required disclosure under PFRS Accounting Standards.

The information on taxes, duties and license fees paid or accrued during the taxable year required under RR No. 15-2010 are presented below and in the succeeding pages.

(a) Output VAT

In 2025, the Company declared output VAT as follows:

<i>Amounts in PHP</i>	<u>Tax Base</u>	<u>Output VAT</u>
Sale of goods:		
Taxable revenues	264,761,377	31,771,366
Exempt revenues	571,030,984	-
Other income	408,837	49,060
	<u>836,201,198</u>	<u>31,820,426</u>

Pursuant to Section 108(B), *Zero-rated VAT on Sale of Service*, and Section 109, *VAT Exempt Transactions*, of the NIRC, as amended, the Company had no zero-rated sales for 2025.

(b) *Input VAT*

The movements in input VAT for the fiscal year ended March 31, 2026 are summarized below (*Amounts in PHP*).

Balance at beginning of year	14,770,782
Importation of goods	29,906,263
Domestic purchase of goods other than capital goods	14,507,439
Purchase of services	7,363,758
Applied against output VAT	(28,179,235)
Input tax allocable to exempt sales	(15,878,941)
Input tax on purchases of capital goods above 1,000,000 deferred for next periods	<u>(4,381,542)</u>
Balance at end of year	<u>18,108,524</u>

The total deferred input VAT amounted to P817,301 as at March 31, 2026 and is presented under Other Assets account in the 2026 statement of financial position.

(c) *Custom Duties*

The Company paid for customs duties amounting to P5,327,588 for the importation of goods for the fiscal year ended March 31, 2026.

(d) *Excise Tax*

The Company does not have any transaction which is subject to excise tax.

(e) *Documentary Stamp tax (DST)*

The Company paid DST related to its insurance policy amounting to P531,862 for the fiscal year ended March 31, 2026.

(f) *Taxes and Licenses*

The summary of Taxes and licenses, reported under Selling and Administrative Expenses in the 2026 statement of comprehensive income is broken down as seen below (*Amounts in PHP*).

Municipal licenses and permits	1,758,152
DST	<u>637,697</u>
	<u>2,395,849</u>

(g) *Withholding Taxes*

The details of total withholding taxes for the year ended March 31, 2026 as follows
(Amounts in PHP):

Compensation and benefits	18,362,954
Expanded	<u>5,228,212</u>
	<u>23,591,166</u>

In 2026, the Company has no final tax paid since it does not have any transactions subject to final tax.

(h) *Deficiency Tax Assessment and Tax Cases*

As of March 31, 2026, the Company does not have any final deficiency tax assessments from the BIR nor does it have tax cases outstanding or pending in courts or bodies outside of the BIR in any of the open taxable years.

23.2 Requirements Under RR No. 34-2020

RR No. 34-2020 prescribes the guidelines and procedures on the submission of BIR Form No. 1709, transfer pricing documentation and other supporting documents for related party transactions. The Company is not covered by these requirements as the Company did not fall in any of the categories identified under Section 2 of RR No. 34-2020. This supplementary information is not a required disclosure under PFRS Accounting Standards.